With a market capitalization (market cap) of $1.07B — a measure of how much the company is worth — Lexicon Pharmaceuticals, Inc. is the 2542nd most valuable company in Healthcare as of August 18, 2026. Shares trade at $2.42, up +3.42% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Visit websiteAs of August 18, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) is worth $1.07B — this is its market capitalization, the total value of all its outstanding shares.
Lexicon Pharmaceuticals, Inc.’s market cap is $1.07B, which ranks it #2542 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Lexicon Pharmaceuticals, Inc. (LXRX) shares trade at $2.42, up 3.42% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025